TY - JOUR
T1 - Mast cell phenotypes in the allograft after lung transplantation
AU - Banga, Amit
AU - Han, Yingchun
AU - Wang, Xiaofeng
AU - Hsieh, Fred H.
N1 - Funding Information:
The authors would like to acknowledge Dr Serpil Erzurum, Department of Pathobiology, Lerner Research Institute, Cleveland Clinic for guidance, input, and helpful discussions regarding the study design. We would also like to thank Dr Carol Farver from the Department of Anatomic Pathology, Cleveland Clinic for assisting with the paraffin embedded TBLB specimens. This work was supported by NIH HL119321 and by a Lerner Research Institute Research Program Committee grant. The authors have no conflict of interest to declare.
Publisher Copyright:
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Background: The burden of mast cell (MC) infiltration and their phenotypes, MC-tryptase (MCT) and MC-tryptase/chymase (MCTC), after lung transplantation (LT) has not been evaluated in human studies. Methods: We reviewed 20 transbronchial lung biopsy (TBLB) specimen from patients with early normal allograft (<6 months post-LT, n=5), late normal allograft (>6 months, n=5), A2 or worse acute cellular rejection (ACR, n=5), and chronic lung allograft dysfunction (CLAD, n=5). Slides were immunostained for tryptase and chymase. Total MC, MCT, MCTC and MCTCto-MCT ratio were compared between the four groups using a generalized linear mixed model. Results: Irrespective of clinicopathologic diagnosis, MC burden tends to increase with time (r2=.56, P=.009). MCTC phenotype was significantly increased in the CLAD group (8.2±4.9 cells per HPF) in comparison with the other three groups (early normal: 1.6±1.7, P=.0026; late normal: 2.5±2.3, P=.048; ACR: 2.7±3.5, P=.021). Further, the ratio of MCTC to MCT was significantly increased in CLAD group as compared to the other three groups (P<.001 for all comparisons). Conclusions: The burden of MC may increase in the allograft as function of time. Patients with CLAD have an increased relative and absolute burden of MCTC phenotype MC. Future studies are needed to confirm these findings and evaluate the potential pathologic role of MCTC in allograft dysfunction.
AB - Background: The burden of mast cell (MC) infiltration and their phenotypes, MC-tryptase (MCT) and MC-tryptase/chymase (MCTC), after lung transplantation (LT) has not been evaluated in human studies. Methods: We reviewed 20 transbronchial lung biopsy (TBLB) specimen from patients with early normal allograft (<6 months post-LT, n=5), late normal allograft (>6 months, n=5), A2 or worse acute cellular rejection (ACR, n=5), and chronic lung allograft dysfunction (CLAD, n=5). Slides were immunostained for tryptase and chymase. Total MC, MCT, MCTC and MCTCto-MCT ratio were compared between the four groups using a generalized linear mixed model. Results: Irrespective of clinicopathologic diagnosis, MC burden tends to increase with time (r2=.56, P=.009). MCTC phenotype was significantly increased in the CLAD group (8.2±4.9 cells per HPF) in comparison with the other three groups (early normal: 1.6±1.7, P=.0026; late normal: 2.5±2.3, P=.048; ACR: 2.7±3.5, P=.021). Further, the ratio of MCTC to MCT was significantly increased in CLAD group as compared to the other three groups (P<.001 for all comparisons). Conclusions: The burden of MC may increase in the allograft as function of time. Patients with CLAD have an increased relative and absolute burden of MCTC phenotype MC. Future studies are needed to confirm these findings and evaluate the potential pathologic role of MCTC in allograft dysfunction.
KW - acute cellular rejection
KW - chronic lung allograft dysfunction
KW - innate immunity
KW - transbronchial lung biopsy
UR - http://www.scopus.com/inward/record.url?scp=84978264420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978264420&partnerID=8YFLogxK
U2 - 10.1111/ctr.12758
DO - 10.1111/ctr.12758
M3 - Article
C2 - 27146340
AN - SCOPUS:84978264420
SN - 0902-0063
VL - 30
SP - 845
EP - 851
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 7
ER -